Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 6Completed 6Active not recruiting 3Terminated 1Enrolling by invitation 1Available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 10CNS 4Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 492Pancreatic Neoplasms 387Carcinoma, Hepatocellular 261Colonic Neoplasms 214Stomach Neoplasms 200Rectal Neoplasms 190Esophageal Neoplasms 157Neoplasms 139Carcinoma, Non-Small-Cell Lung 133Liver Neoplasms 129Neoplasm Metastasis 124Breast Neoplasms 102Cholangiocarcinoma 94Melanoma 85Ovarian Neoplasms 79Lung Neoplasms 72Squamous Cell Carcinoma of Head and Neck 57Carcinoma, Renal Cell 57Gastrointestinal Neoplasms 55Sarcoma 46Biliary Tract Neoplasms 39Prostatic Neoplasms 36Head and Neck Neoplasms 36Esophageal Squamous Cell Carcinoma 36Adenocarcinoma Of Esophagus 36Urinary Bladder Neoplasms 33Adenocarcinoma 33Uterine Cervical Neoplasms 31Triple Negative Breast Neoplasms 31Gastrointestinal Stromal Tumors 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neurofibrosarcoma × Gastrointestinal × Clear all
NCT05275478 2026-04-15

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Tango Therapeutics, Inc.

Phase 1/2 Terminated
110 enrolled
CNSGastrointestinalOther solid neoplasmSarcomaThoracic

Glioblastoma, Mesothelioma, Sarcoma, Cholangiocarcinoma, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡